Medidata Solutions Inc (MDSO) Receives $85.88 Consensus Price Target from Analysts
Shares of Medidata Solutions Inc (NASDAQ:MDSO) have been given a consensus recommendation of “Hold” by the thirteen brokerages that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and six have issued a buy recommendation on the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $85.88.
Several brokerages recently issued reports on MDSO. ValuEngine upgraded shares of Medidata Solutions from a “hold” rating to a “buy” rating in a report on Friday, August 24th. BidaskClub upgraded shares of Medidata Solutions from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 16th. Royal Bank of Canada dropped their target price on shares of Medidata Solutions to $91.00 and set an “outperform” rating on the stock in a report on Tuesday, September 25th. Piper Jaffray Companies dropped their target price on shares of Medidata Solutions from $96.00 to $93.00 in a report on Thursday, October 18th. Finally, JPMorgan Chase & Co. dropped their target price on shares of Medidata Solutions to $74.00 and set a “neutral” rating on the stock in a report on Friday, October 19th.
Shares of MDSO stock opened at $74.52 on Monday. Medidata Solutions has a 12-month low of $59.60 and a 12-month high of $88.87. The company has a debt-to-equity ratio of 0.15, a quick ratio of 2.52 and a current ratio of 2.52. The company has a market capitalization of $4.62 billion, a P/E ratio of 87.67, a P/E/G ratio of 4.47 and a beta of 1.30.
In other Medidata Solutions news, CFO Rouven Bergmann sold 10,000 shares of the stock in a transaction that occurred on Monday, December 3rd. The shares were sold at an average price of $79.00, for a total value of $790,000.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Michael Pray sold 7,000 shares of the stock in a transaction that occurred on Monday, November 26th. The stock was sold at an average price of $73.02, for a total transaction of $511,140.00. Following the completion of the transaction, the executive vice president now owns 52,408 shares in the company, valued at $3,826,832.16. The disclosure for this sale can be found here. Insiders sold 34,030 shares of company stock worth $2,539,022 over the last quarter. Insiders own 4.70% of the company’s stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in MDSO. Man Group plc bought a new stake in shares of Medidata Solutions during the 3rd quarter valued at $205,000. First Republic Investment Management Inc. bought a new stake in shares of Medidata Solutions during the 2nd quarter valued at $242,000. Quantbot Technologies LP bought a new stake in shares of Medidata Solutions during the 3rd quarter valued at $229,000. Zions Bancorporation bought a new stake in shares of Medidata Solutions during the 2nd quarter valued at $274,000. Finally, Gideon Capital Advisors Inc. bought a new stake in shares of Medidata Solutions during the 3rd quarter valued at $263,000.
Medidata Solutions Company Profile
Medidata Solutions, Inc provides cloud-based solutions for life sciences worldwide. It offers the Medidata Clinical Cloud, a platform, pioneering analytics, and clinical technology for the development of new therapies. The company's platform solutions include data capture and management and trial planning and management.
Featured Article: What is a Fiduciary?
Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.